This company has been acquired
PETQ Stock Overview
Operates as a pet medication and wellness company in the United States and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 3/6 |
| Past Performance | 2/6 |
| Financial Health | 2/6 |
| Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
PetIQ, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$30.98 |
| 52 Week High | US$31.06 |
| 52 Week Low | US$15.09 |
| Beta | 1.74 |
| 1 Month Change | 0.72% |
| 3 Month Change | 41.53% |
| 1 Year Change | 66.47% |
| 3 Year Change | 30.61% |
| 5 Year Change | 25.32% |
| Change since IPO | 32.85% |
Recent News & Updates
Does PetIQ (NASDAQ:PETQ) Have A Healthy Balance Sheet?
Aug 14
PetIQ: Attractive Acquisition Offer After Strong Earnings Growth In Q2
Aug 09Recent updates
Does PetIQ (NASDAQ:PETQ) Have A Healthy Balance Sheet?
Aug 14PetIQ: Attractive Acquisition Offer After Strong Earnings Growth In Q2
Aug 09PetIQ: Product Margin Gains Offset By Higher Marketing Spend
Jul 09White Brook Capital - PetIQ: Guidance And Street Estimates Are Too Conservative
Apr 20PetIQ (NASDAQ:PETQ) Seems To Use Debt Quite Sensibly
Apr 13PetIQ: Cost Savings, Higher EBITDA Suggest A Potential Valuation Re-Rate
Feb 06Investors Will Want PetIQ's (NASDAQ:PETQ) Growth In ROCE To Persist
Sep 15PetIQ, Inc. (NASDAQ:PETQ) Stock Rockets 26% But Many Are Still Ignoring The Company
Aug 16PetIQ (NASDAQ:PETQ) Has A Somewhat Strained Balance Sheet
Aug 10PetIQ's (NASDAQ:PETQ) Returns On Capital Are Heading Higher
Jun 14PetIQ (NASDAQ:PETQ) May Have Issues Allocating Its Capital
Feb 11PetIQ gains 1.84 % on $30M stock repurchase program
Sep 06PetIQ (NASDAQ:PETQ) Use Of Debt Could Be Considered Risky
Aug 23Here's What's Concerning About PetIQ's (NASDAQ:PETQ) Returns On Capital
Jul 27Is PetIQ (NASDAQ:PETQ) Using Too Much Debt?
May 06There Are Reasons To Feel Uneasy About PetIQ's (NASDAQ:PETQ) Returns On Capital
Apr 02The Prognosis For PetIQ
Feb 12PetIQ: Economies Of Scale Will Kick In Eventually
Jan 03Shareholder Returns
| PETQ | US Healthcare | US Market | |
|---|---|---|---|
| 7D | 0.2% | 0.7% | -0.2% |
| 1Y | 66.5% | -10.7% | 25.8% |
Return vs Industry: PETQ exceeded the US Healthcare industry which returned 2.4% over the past year.
Return vs Market: PETQ exceeded the US Market which returned 38.1% over the past year.
Price Volatility
| PETQ volatility | |
|---|---|
| PETQ Average Weekly Movement | 13.4% |
| Healthcare Industry Average Movement | 7.6% |
| Market Average Movement | 6.4% |
| 10% most volatile stocks in US Market | 18.6% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: PETQ's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: PETQ's weekly volatility has increased from 8% to 13% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2010 | 1,527 | Cord Christensen | petiq.com |
PetIQ, Inc. operates as a pet medication and wellness company in the United States and internationally. It operates in two segments, Products and Services. The company offers Rx pet medications, which sells flea and tick control, heartworm preventatives, arthritis, thyroid, diabetes and pain treatments, antibiotics, and other specialty medications; and develops and manufactures its own proprietary value-branded products, as well as third-party branded products for dogs and cats.
PetIQ, Inc. Fundamentals Summary
| PETQ fundamental statistics | |
|---|---|
| Market cap | US$926.64m |
| Earnings (TTM) | US$13.19m |
| Revenue (TTM) | US$1.13b |
69.7x
P/E Ratio0.8x
P/S RatioIs PETQ overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| PETQ income statement (TTM) | |
|---|---|
| Revenue | US$1.13b |
| Cost of Revenue | US$854.90m |
| Gross Profit | US$279.43m |
| Other Expenses | US$266.23m |
| Earnings | US$13.19m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 0.44 |
| Gross Margin | 24.63% |
| Net Profit Margin | 1.16% |
| Debt/Equity Ratio | 170.0% |
How did PETQ perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/10/24 02:43 |
| End of Day Share Price | 2024/10/24 00:00 |
| Earnings | 2024/06/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
PetIQ, Inc. is covered by 8 analysts. 5 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| John Lawrence | Benchmark Company |
| David Westenberg | CL King & Associates, Inc. |
| David Westenberg | Guggenheim Securities, LLC |